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Of evaluable pts with chimerism data, median time to 100%
donor chimerism was day 28 for CD33 and day 180 for
CD3. AGVHD occurred in 42/60 (70%) pts (grade I in 14 and
grades II-IV in 28), and cGVHD occurred in 28/52 (54%); 12
pts developed extensive cGVHD. 14 pts required donor lym-
phocyte infusion for disease progression. 100-day NRM was
10% (all from aGVHD); another 2 patients died of disease
progression. After day 100, most pts died from disease pro-
gression or infection related to cGVHD. Kaplan-Meier proba-
bilities for overall survival (OS) and progression free survival
(PFS) at one year were 61% and 48%, respectively with median
follow up of 505 days (range 31-2029). OS at 2 and 3 years was
45% and 36%. In univariate analysis, the development of
cGVHD signiﬁcantly correlated with improved OS (p  0.02)
and PFS (p  0.01). Although CD34 and CD3 doses showed
no signiﬁcant association with development of cGVHD, higher
doses of both were associated with development of aGVHD (p
 0.01 and 0.04 respectively) and higher CD34 doses (6.8 vs
9.4106/kg) were associated with development of higher grades
of aGVHD (grades II-IV versus grades 0-I) (p  0.01). Incre-
mental increases in CD34 dose were associated with an in-
creased hazard ratio for death; however, a dose above 8 106
CD34/kg was associated with lower probability of relapse (p 
0.04). NM conditioning has a role in alloPBSCT and further
investigation to optimize disease indications and CD34 dosing
is needed.
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RAPAMYCIN GENERATED DONOR TH2/TC2 CELLS PREVENT GRAFT
REJECTION BY INHIBITION OF ALLOREACTIVITY AND NOT BY DELE-
TION OF ALLOREACTIVE T CELLS
Mariotti, J.1, Foley, J.1, Wong, E.1, Borenstein, T.1, Han, S.1,
Hanson, J.1, Fowler, D.H.1 1National Cancer Institute/NIH, Bethesda,
MD.
Ex vivo rapamycin generates murine Th2 cells that potently
abrogate GVHD. We thus hypothesized that rapamycin would
generate Th2/Tc2 cells (Th2/Tc2.R cells) that prevent fully
MHC-disparate hematopoietic stem cell (HSC) rejection. To
test this hypothesis, we utilized a model of rejection involving
lethal host irradiation and quantitative host T cell addback [see
cohorts, Table]. Th2/Tc2.R cell recipients had consistent allo-
engraftment (99% donor, n9/10; rejection, n1/10); in con-
trast, control Th2/Tc2 recipients had graft rejection (n9/10)
or mixed chimerism (n1/10). Post-BMT host-vs-graft re-
sponses (HVGR) were quantiﬁed by the following method: (a)
spleen cell harvest and enumeration; (b) 24 h host (syngeneic) or
donor (allogeneic) dendritic cell stimulation; (c) cell-surface
ﬂow cytometry with anti-CD4, anti-CD8 and anti-host antibod-
ies; (d) Miltenyi IFN-gamma cytokine capture ﬂow cytometry;
and (d) calculation of absolute number of host anti-donor allo-
reactive CD4 and CD8 T cells per spleen. Graft rejection
controls had increased post-BMT allospeciﬁc CD4 and
CD8 T cells secreting IFN-g (cohort 3cohort 2; p .001).
Prevention of rejection by donor Th2/Tc2.R cells abrogated
this HVGR (cohort 5cohort 3; p .001); in contrast, donor
Th2/Tc2 cells only partially reduced HVGR (cohort 4cohort
3; p .05). Cohorts 6, 7, 8, and 9 demonstrated that rapamycin-
generated donor T cells prevention of HVGR was attributable
to both CD4 and CD8 subsets and occurred independent of
perforin or fasL molecules associated with clonal deletion
mechansims. To evaluate whether alloreactive host T cells were
clonally deleted, the fate of 2C TCR transgenic T cells utilized
as host T cell addback was evaluated [BALB/c(H-2d) into B6(H-
2b) model]. Administration of a low-dose of donor Th2/Tc2.R
cells relative to host 2C TCR transgenic cells (200:1 ratio)
resulted in actual massive expansion of alloreactive 2C cells
(cohort 13 cohort 11, p.0001), increased allospeciﬁc IFN-g
release from 2C cells, and a resultant decrease in donor chimer-
ism; in contrast, administration of high-dose Th2/Tc2.R cells
(1000:1 ratio) resulted in similar expansion of alloreactive 2C
cells, but nominal acquisition allospeciﬁc IFN-g secretion
(94.480  13.030; cohort 14 vs cohort 13, p.0005) and in-
creased donor chimerism (p.0001). Taken together, rapamy-
cin-generated Th2 or Tc2 cells prevent rejection by a mecha-
nism that reduces host allospeciﬁcity without allospeciﬁc clonal
deletion.
Th2/Tc2R Cells: Abrogation of T cell mediated HVGR without
Deletion of Host Alloreactive T cells
B6 into BALB/c (Inocula)
Absolute #
CD8IFN-g
alloreactive
host T
(x10^3/spleen)
% Donor
cells
Cohort
1 HSC - 87  1
2 Host T 18  3 -
3 HSCHost T Addback 2,600  260 46  3
4 HSCHost Tcontrol T2 980  265 75  4
5 HSCHost TT2.R 48  9 92  1
6 HSCHost TTh2.R (CD4) 284  87 92  1
7 HSCHost TTc2.R (CD8) 142  42 89  1
8 HSCHost TT2.R PFN KO 32  8 97  1
9 HSCHost TT2.R FASL KO 4  2 98  0.1
BALB/c into B6 (Inocula; 2C
TCR Host Add-back)
Absolute # of
2C TCR
Alloreactive
host T
(x10^3/spleen)
% Donor
cells
10 BM - 11  1
11 Host T 46  10 -
12 BMHost T 19  2 3  1
13 BM Host T T2.R 200:1 1,182  125 10  1
14 BM Host T T2.R 1000:1 959  68 77  2
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HYPERGLYCEMIA DURING NEUTROPENIA WAS ASSOCIATED WITH
POOR OUTCOME IN PATIENTS UNDERGOING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT)
Fuji, S.1, Kim, S.-W.1, Mori, S.-I.1, Fukuda, T.1, Kamiya, S.2,
Yamasaki, S.1, Tanosaki, R.1, Tobinai, K.1, Takaue, Y.1 1Department of
Hematology and Stem Cell Transplantation National Cancer Center
Hospital, Tsukiji, Tokyo, Japan; 2Department of Nutrition National
Cancer Center Hospital, Tsukiji, Tokyo, Japan.
Background Recipients of allogeneic HSCT frequently require
support with parenteral nutrition and immunosuppressive drugs, in
expectation of an increased risk of infections associated with hy-
perglycemia, particularly in the neutropenic period. Previous re-
ports showed that hyperglycemia was associated with morbidity
and mortality in ICU (ref van den Verge et al. N Engl J Med. 2001
Nov 8;345(19): 1359-67). There was no previous study which
assessed the clinical impact of hyperglycemia in patients undergo-
ing myeloablative HSCT. Patients and Methods A cohort of 112
consecutive adult patients with hematological malignancies treated
between January 2002 and June 2006 was reviewed retrospectively,
and 21 patients were excluded due to graft failure, preexisting
infectious diseases or preexisting neutropenia. The remaining 91
patients (Age median 35.5, 18-57) were categorized according to
mean fasting blood glucose (BG) level in the neutropenic period: 1)
“normoglycemia” (BG110 mg/dl, n28), 2) “mild hyperglyce-
mia” (110BG150 mg/dl, n49) and 3) “moderate and severe
hyperglycemia” (150 mg/dlBG, n14). Conditioning regimens
included BU/CY (n45), CY/TBI (n43) and CA/CY/TBI (n3).
GVHD prophylaxis included cyclosporine- (n62) and tacroli-
mus-based regimens (n29). Stem cell sources included bone mar-
row (n46), peripheral blood (n41) and cord blood cells (n4).
The primary endpoint of this study was the occurrence of febrile
neutropenia (FN) and infection during neutropenia. The second-
ary endpoints were parameters for organ dysfunction, aGVHD,
overall survival (OS) and treatment-related mortality (TRM). Re-
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sults There was no signiﬁcant difference between the 3 groups in
the occurrence of FN or documented infection. However, hyper-
glycemia was signiﬁcantly associated with organ dysfunction and
aGVHD. OS was better and TRM was less in group1 compared
with group2 and group3. Conclusion Degrees of hyperglycemia
during neutropenia was associated with an increased risk of organ
dysfunction and aGVHD, which further led to higher TRM and
lower OS. These results support the possibility that intensive
glucose control reduces morbidity and mortality after HSCT.
blood glucose level
normoglycemia
(n28)
mild
hyperglycemia
(n49)
moderate and
severe
hyperglycemia
(n14)
FN 25 (89%) 43 (88%) 13 (93%)
Documented infection 9 (32%) 10 (20%) 6 (43%)
hypercreatininemia (serum
creatinine>2mg/dl or
more than twice of
baseline) 1 (4%) 4 (8%) 4 (29%)
hyperbilirubinemia (serum
bilirubin>2 mg/dl) 3 (11%) 11 (22%) 6 (43%)
CRP elevation (serum
CRP>15 mg/dl) 4 (14%) 15 (31%) 9 (64%)
aGVHD (II-IV) 4 (14%) 18 (38%) 7 (58%)
OS (1-year) 87% 70% 56%
TRM (1-year) 5% 17% 30%
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THROMBOTIC MICROANGIOPATHY AFTER HSCT: MUCOSITIS AS A RISK
FACTOR FOR SURVIVAL AND HIGH PREVALENCE OF ACUTE GVHD, CMV
AND GRAM POSITIVE INFECTIONS
Funke, V.A.M.1, Oliveira, M.M.1, Ruiz, J.1, Bonﬁm, C.M.1,
Bitencourt, M.A.1, Coutinho, E.N.1, Setubal, D.C.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
Federal do Parana, Curitiba, PR, Brazil.
INTRODUCTION: Thrombotic microangiopathy is a rare
complication after HSCT. Given the different pathophisiology of
the disease and high mortality observed, our purpose is evaluating
clinical carcteristcs of these patients and risk factors for survival.
PATIENTS AND METHODS: From 1991to 2004, 1066
HSCT were performed at HC-UFPR (Curitiba, Brazil). We iden-
tiﬁed in our database 17 patients with the diagnosis of thrombotic
microangiopathy (prevalence of 1.6%). M4/F13, Median
age(y)11; Diagnosis included: SAA: 2; Fanconi anemia: 4; Acute
leukemias: 7, Others 2.
Conditioning regimen consisted of BUCY in 9/17 (52%); CI 
TBI in 3/17 (18%) of the patients, NMA regimens in 18% and
others in 12% of the patients. Immunephrophylaxis
consisted of CSA and MTX in 52% of the patients.Twelve
patients received related and ﬁve received unrelated donor trans-
plant.
Marrow was the stem cell source in all but one patient who
received cord blood.
Twelve patients were HLA identical, three patients had a class
one mismatch, one patients had a class II mismatch and one patient
had more than one mismatch.
Median number of cells infused were 2,57  108/KG.
RESULTS A-GVHD grade II-IV was present in 12 (70%) pa-
tients and extensive C-GVHD was present in only 18% of the
patients. Median survival was 99 days and estimated overall survival
in 25 years is only 15%, despite therapy. Infection was present in
all but one patient (94%). Ten patients had serious bacterial in-
fections (58%), eight of them by gram-positive bacteria. Fungal
infection was identiﬁed in ﬁve patients (2 Candida sp and 3 As-
pergillus sp). Viral infection was identiﬁed in 12 patients (eight of
them with CMV positive antigenemia). Causes of death included:
A-GVHD in four pt, C-GVHD in 2 patients, infection in 6
patients, bleeding in two patients and persistent disease in one
patient. The only signiﬁcant factor for survival was severe mucosi-
tis (more than grade II).
CONCLUSION: 1. OS was extremely low (15%) despite ther-
apy; 2. Infection ( specially gram-positive bacterial infections and
CMV positive antigenemia) was present at the majority of the
patients and was the main cause of death; 3. A-GVHD was present
in 52% of the patients; 4. Severe mucositis was associated to a
lower survival rate (p0,02).
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LONG TERM RESULTS OF ALLOGENEIC STEM CELL TRANSPLANT FOR
CML IN PEDIATRIC PATIENTS: A STUDY OF 50 CASES TRANSPLANTED
OVER 20 YEARS IN A SINGLE INSTITUTION
Funke, V.A.M.1, Pettengill, C.1, Bonﬁm, C.M.1, Ruiz, J.1,
Azambuja, A.P.1, Medeiros, L.1, Setubal, D.C.1, Bitencourt, M.A.1,
Oliveira, M.M.1, Coutinho, E.N.1, Zanis-neto, J.1, de Medeiros, C.P.1,
Pasquini, R.1 1Hospital de Clinicas - Universidade Federal do Parana,
Curitiba, PR, Brazil.
Introduction: Chronic myeloid leukemia (CML) accounts for
2-3% of the leukemias in childhood. The only potential curative
treatment is allogeneic hematopoietic stem cell transplantation
(HSCT), although promising results achieved with imatinib me-
sylate in adults substantiate its use as a therapeutic alternative for
children. The aim of this study is to analyze the outcomes of
HSCT in pediatric patients regarding overall survival (OS) and
main causes of death.
Materials and methods: Retrospective analysis of children aged
1-17 years, diagnosed with CML who underwent HSCT in a single
institution in Brazil between jan/1984 and aug/2005. Survival was
estimated by Kaplan-Meier curves. Log Rank test was used for
comparison of continuous variables.
Results: Fifty patients were assessed, 31 male and 19 female.
Median age of 13,5 years (1-17). Forty one patients (82%) were in
ﬁrst chronic phase (CP1) and 9 in advanced phases. The interval
between diagnosis and HSCT had a median time of 17,5 months
(5-84). The source of stem cells was bone marrow in 44 patients
(88%), umbilical cord blood in 5 (10%) and peripheral blood stem
cell in 1 (2%). Thirty nine patients (78%) underwent related
HSCT and 11 (22%) unrelated donor HSCT. Conditioning reg-
imens: busulfan and cyclophosphamide in 35 patients (70%) and
TBI containing regimens in 15 (30%). Complete engraftment
occurred in 82% of the transplants. Acute (a) graft-versus-host-
disease (GVHD) grades II-IV occurred in 44% of the patients,
with 20% grade IV. Extensive chronic (c) GVHD occurred in
15/40 patients (38%). Fifteen patients (32%) relapsed after HSCT.
Mortality in the study population was 48% and the main causes of
death were: relapse in 6 patients (25%), a-GVHD in 6 (25%) and
c-GVHD in 4 (17%). Estimated OS in 20 years was 50%, with a
median survival of 1926 days. When analyzed separately, patients
in CP1 who received related HSCT and immuneprophilaxis with
three drugs (steroids, cyclosporine and methotrexate) had an esti-
mated OS in 20 years of 70%.
Conclusions: 1) Long term follow up of these children with
CML who underwent allogeneic HSCT demonstrate an OS of
50%, reaching 70% in low risk patients. 2) Main causes of death
were relapse, acute and chronic GVHD.
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RISK FACTOR ANALISIS FOR SURVIVAL IN 125 UNRELATED TRANS-
PLANTS FOR MALIGNANT DISEASES PERFORMED OVER TEN YEARS IN
A SINGLE CENTER IN BRAZIL
Funke, V.A.M.1, Coutinho, E.N.1, Setubal, D.C.1, Ruiz, J.1,
Bonﬁm, C.M.1, Bittencourt, M.A.1, Oliveira, M.M.1, Zanis-Neto, J.1,
de Medeiros, C.P.1, Pasquini, R.1 1Hospital de Clinicas - Universidade
Federal do Parana, Curitiba, PR, Brazil.
INTRODUCTION: Unrelated transplants are incresingly used
for therapy of malignant diseases. The objective of this study is
evaluating risk factors for overall survival among 125 unrelated
transplants performed at the BMT center of HC-UFPR in Cu-
ritiba, Brazil.
PATIENTS AND METHODS: we analyzed results of unre-
lated HSCT performed from 07/95 to 06/05.Kaplan Meier was
used to estimate overall survival. Log rank test was used to compare
survival curves and Fisher’s exact test for comparison of categoric
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